KZR earnings analysis
What we found in KZR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Kezar Life Sciences, Inc. has reported a significant reduction in losses for Q1 2026 compared to the previous year, with a net loss of $5.8 million, down from $16.6 million in Q1 2025, indicating improved operational efficiency amidst ongoing challenges, including a merger with Aurinia Pharma. Total operating expenses decreased sharply by $10.3 million, reflecting restructuring efforts and a strategic focus on cost management.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Reduced Net Loss
- Kezar's net loss decreased to $5.8 million for Q1 2026 from $16.6 million in Q1 2025, a $10.8 million improvement.
- Lower Operating Expenses
- Total operating expenses fell to $7.4 million, down from $17.7 million year over year, a reduction of $10.3 million.
- Collaboration Revenue from Everest
- The company continues to expect fluctuations in collaboration revenues based on milestone payments from its partnership with Everest Medicines.
- Interest Expense Fully Terminated
- Interest expense decreased to $0 for Q1 2026, down from $0.3 million in Q1 2025, due to the repayment of the loan facility.
- Cash Position Persists
- As of March 31, 2026, Kezar maintains $66.2 million in cash and equivalents to support operations.
- Cost Reduction Measures
- Research and development expenses were reduced to $1.5 million in Q1 2026, from $12.2 million in the same quarter last year, a decrease of $10.7 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Merger Completion Uncertainty
- The potential Merger with Aurinia Pharma U.S. may not be completed by June 28, 2026, posing risks to company stability.
- Strategic Alternatives Constraints
- Expected complications and indecisiveness in pursuing strategic alternatives could impair future operations.
- Potential Litigation Risks
- Ongoing merger activities might lead to litigation that distracts management and incurs additional costs.
What they said about what is next.
Outlook deferred to earnings press release/call.
The filing reads better than the one before it.
What came before.
- 10-K · April 30, 2026
- Kezar Life Sciences, Inc. continues to navigate a challenging financial landscape with significant operational transitions, particularly associated with the recent merger with Aurinia Pharma. The company reported a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KZR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever